was successfully added to your cart.



Our article in Nature’s Biopharma Dealmakers ‘Industry shows trust in cell and gene therapy platform technologies’

By | Business Development, Valuation | No Comments

We were asked to share our insights on cell and gene therapy deals and financing in the renowned scientific publication Biopharma Dealmakers by Nature. The take-away: these companies continued to attract large deals in 2022 despite the financing landscape looking gloomier than ever.

The CGT space keeps breaking ground and continues to hold promise for treatment paradigm shifts. 

Read the full article titled ‘Industry shows trust in cell and gene therapy platform technologies’ via Nature’s website. Our cell and gene therapy expert Stephanie Mattsson, management consultant, and deal expert Johan Olsson, senior management consultant, at MSC authored the article.

Access article >

Cover photo by Siarhei Yurchanka / Alamy Stock Photo.

Our masterclass at LSX 2021 on leveraging Biotech Valuations

By | Company update, Valuation | No Comments

Early September 2021, we held the first valuation masterclass at partnering and investor conference LSX. We heard that it became the most attended class which underlines the high interest of successfully using valuation in out-licensing and investor discussions; and the lack of information tailored to the unique Nordic biotech space. Therefore, we are now also running courses to support biotech executives in better understanding and utilizing biotech valuations in crucial negotiations. Watch the masterclass recording or learn more about our valuation courses below.

Join our Fundamentals of Biotech Valuations course to ace valuations in the unique Nordic biotech space. Next session is on October 13, 2021. Sign up here: https://mscnordics.com/product/biotech-valuations-fundamentals/

Did you miss our Biotech Valuation masterclass at LSX? Check out the recording about using Biotech Valuations to best prepare for out-licensing and investments.